A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients

Efficacy of PA21 (sucroferric oxyhydroxide), a novel calcium-free polynuclear iron(III)-oxyhydroxide phosphate binder, was compared with that of sevelamer carbonate in an open-label, randomized, active-controlled phase III study. Seven hundred and seven hemo- and peritoneal dialysis patients with hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Floege, Jürgen, Covic, Adrian C, Ketteler, Markus, Rastogi, Anjay, Chong, Edward M F, Gaillard, Sylvain, Lisk, Laura J, Sprague, Stuart M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150998/
https://www.ncbi.nlm.nih.gov/pubmed/24646861
http://dx.doi.org/10.1038/ki.2014.58

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150998/
https://www.ncbi.nlm.nih.gov/pubmed/24646861
http://dx.doi.org/10.1038/ki.2014.58

Ejemplares similares